CSL Limited (ASX:CSL) has placed $US750 million of debt into the US private placement market according to a report by the Australian Financial Review.
It’s one of the largest ever issues by an Australian company in this market. It’s triple the size of the Australian pharmaceutical giant’s original plan announced a fortnight ago.
In August the company advised that it planned to raise around $US1 billion of debt though US private placements and bank loans.
CSL reported a net profit of $941 million for the year to June 30, 2011.
